Seeing that the patents for several blockbuster monoclonal antibody drugs are going to expire, including Roche's Rituximab (US$5.4 billion annual global sales) due in 2013 and Roche's Bevacizumab(US$5.5 billion annual global...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)